Fuji highlights CR mammography, new mammo capabilities in Synapse
Fujifilm Medical Systems at RSNA 2006 showcased its Computed Radiography for Mammography (FCRm) system and announced its new generation PACS Synapse version 3.2 will include additional digital mammography capabilities.
At the show, Fuji revealed a distribution agreement with Siemens Medical Solutions for its FCRm system. In addition to FCRm being sold by Fuji’s direct sales force, Siemens will be adding Fuji’s FCRm FFDM system to its product portfolio for both new and existing Siemens’ customers.
Fuji said the company’s CR system was a major participant in the Digital Mammographic Imaging Screening Trial (DMIST) that found digital mammograms to be more accurate than film screen mammograms for significant sub-groups of the screening population. Fuji’s FFDM system was the second most used, and the only CR-based digital mammography system, in the clinical study of 49,528 women, Fuji said.
Fuji announced that the FCRm has been selected for install at two breast imaging organizations: University of North Carolina, Chapel Hill (UNC), and Solis Women’s Health in Austin, Texas. UNC was one of the acquisition sites for DMIST, the company said.
According to Fuji, its Synapse v. 3.2 will further assist facilities with the unique workflow, visualization and image processing needs that the interpretation of FFDM studies presents. Digital mammography has a unique workflow that includes screening and diagnostic workflows, as well as the critical need for comparison models, multi-modality display capabilities and the integration of CAD results. Fuji’s Synapse v. 3.2 will extend Fuji’s reading protocol technology to enable reader-specific preferences to be set, providing for efficient and consistent screening workflows, and the flexibility to accommodate the unique challenges presented by diagnostic exams. And because Synapse is a multi-modality tool, not just a mammography tool, FFDM data can be integrated into the existing continuum of women’s health care imaging that includes ultrasound and MR, while still using these reader-specific preferences, Fuji said.
In addition, Fuji said it developed a new class of visualization tools focused on other digital diagnostic breast screening examinations. Synapse 3.2 will provide specific features to enhance the presentation of this critical image data, such as support for MQSA compliant overlays, the integration of CAD into the technologist and radiologist workflow, and support for Fuji’s high quality AON compression algorithm.
At the show, Fuji revealed a distribution agreement with Siemens Medical Solutions for its FCRm system. In addition to FCRm being sold by Fuji’s direct sales force, Siemens will be adding Fuji’s FCRm FFDM system to its product portfolio for both new and existing Siemens’ customers.
Fuji said the company’s CR system was a major participant in the Digital Mammographic Imaging Screening Trial (DMIST) that found digital mammograms to be more accurate than film screen mammograms for significant sub-groups of the screening population. Fuji’s FFDM system was the second most used, and the only CR-based digital mammography system, in the clinical study of 49,528 women, Fuji said.
Fuji announced that the FCRm has been selected for install at two breast imaging organizations: University of North Carolina, Chapel Hill (UNC), and Solis Women’s Health in Austin, Texas. UNC was one of the acquisition sites for DMIST, the company said.
According to Fuji, its Synapse v. 3.2 will further assist facilities with the unique workflow, visualization and image processing needs that the interpretation of FFDM studies presents. Digital mammography has a unique workflow that includes screening and diagnostic workflows, as well as the critical need for comparison models, multi-modality display capabilities and the integration of CAD results. Fuji’s Synapse v. 3.2 will extend Fuji’s reading protocol technology to enable reader-specific preferences to be set, providing for efficient and consistent screening workflows, and the flexibility to accommodate the unique challenges presented by diagnostic exams. And because Synapse is a multi-modality tool, not just a mammography tool, FFDM data can be integrated into the existing continuum of women’s health care imaging that includes ultrasound and MR, while still using these reader-specific preferences, Fuji said.
In addition, Fuji said it developed a new class of visualization tools focused on other digital diagnostic breast screening examinations. Synapse 3.2 will provide specific features to enhance the presentation of this critical image data, such as support for MQSA compliant overlays, the integration of CAD into the technologist and radiologist workflow, and support for Fuji’s high quality AON compression algorithm.